OMCL icon

Omnicell

27.34 USD
-1.44
5.00%
At close May 21, 4:00 PM EDT
Pre-market
28.79
+1.45
5.30%
1 day
-5.00%
5 days
-4.20%
1 month
-7.79%
3 months
-31.17%
6 months
-38.02%
Year to date
-38.31%
1 year
-14.32%
5 years
-57.63%
10 years
-24.58%
 

About: Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Employees: 3,670

0
Funds holding %
of 7,245 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

49% more call options, than puts

Call options by funds: $2.7M | Put options by funds: $1.81M

13% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 89

0.34% more ownership

Funds ownership: 99.81% [Q4 2024] → 100.15% (+0.34%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

3% less funds holding

Funds holding: 276 [Q4 2024] → 269 (-7) [Q1 2025]

11% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 38

20% less capital invested

Capital invested by funds: $2.06B [Q4 2024] → $1.64B (-$422M) [Q1 2025]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$35
28%
upside
Avg. target
$37
35%
upside
High target
$40
46%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Wells Fargo
Stan Berenshteyn
28%upside
$35
Overweight
Upgraded
14 May 2025
Benchmark
Bill Sutherland
46%upside
$40
Buy
Maintained
7 May 2025
JP Morgan
Anne Samuel
32%upside
$36
Neutral
Maintained
20 Mar 2025

Financial journalist opinion

Based on 10 articles about OMCL published over the past 30 days

Positive
Zacks Investment Research
6 days ago
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
OMCL unveils new offerings for the perioperative and clinic setting.
Omnicell's New Perioperative Clinic Setting Products May Boost Stock
Neutral
Business Wire
1 week ago
Omnicell Announces New Products for Perioperative and Clinic Settings
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces New Products for Perioperative and Clinic Settings.
Omnicell Announces New Products for Perioperative and Clinic Settings
Neutral
Business Wire
1 week ago
Omnicell Opens New Innovation Lab in Austin, Texas
AUSTIN, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new technologies that are designed to solve evolving challenges faced by the healthcare industry. As hospitals.
Omnicell Opens New Innovation Lab in Austin, Texas
Negative
Seeking Alpha
2 weeks ago
Omnicell: Facing New Headwinds
Omnicell, Inc., a small cap medical technology solutions provider, posted its Q1 results Tuesday.  Both top and the bottom-line results beat the consensus. However, thanks to some new headlines and reduced forward guidance, OMCL shares sold off 15% in trading yesterday. A buying opportunity?  An analysis around Omnicell follows in the paragraphs below.
Omnicell: Facing New Headwinds
Positive
Zacks Investment Research
2 weeks ago
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell Q1 Earnings & Revenues Beat, '25 EPS View Down, Stock Up
Neutral
Seeking Alpha
2 weeks ago
Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript
Omnicell, Inc. (NASDAQ:OMCL ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Kathleen Nemeth - SVP, IR Randall Lipps - Founder, Chairman, President and CEO Nchacha Etta - EVP and CFO Nnamdi Njoku - COO Conference Call Participants Jessica Datson - Piper Sandler Gene Mannheimer - Freedom Capital Markets Allen Lutz - Bank of America Bill Sutherland - Benchmark Stan Berenshteyn - Wells Fargo Matt Hewitt - Craig-Hallum Capital David Larsen - BTIG Operator Good morning, my name is Carly and I will be your conference operator today. At this time, I would like to welcome everyone to the Omnicell First Quarter 2025 Financial Results Conference Call.
Omnicell, Inc. (OMCL) Q1 2025 Earnings Conference Call Transcript
Positive
Zacks Investment Research
2 weeks ago
Omnicell (OMCL) Beats Q1 Earnings and Revenue Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.03 per share a year ago.
Omnicell (OMCL) Beats Q1 Earnings and Revenue Estimates
Neutral
Business Wire
2 weeks ago
Omnicell Announces First Quarter 2025 Results
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces First Quarter 2025 Results.
Omnicell Announces First Quarter 2025 Results
Positive
Zacks Investment Research
3 weeks ago
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
Neutral
Zacks Investment Research
4 weeks ago
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to the strong performance of the SaaS and Expert Services portfolio.
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
Charts implemented using Lightweight Charts™